The explosion of GLP-1 prescriptions — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) — has created one of the most complicated billing environments in outpatient medicine. Not because the coding is complex, but because payer coverage policies are changing faster than most billing teams can track.
A drug that was covered for Type 2 diabetes last month may no longer be covered for weight loss this month. A patient who had coverage under their employer plan may lose it after an annual benefits reset. A prior authorization that was approved for 90 days may require re-authorization with additional documentation at renewal. And the same drug may be covered under one patient’s plan with zero prior auth and completely excluded from another patient’s plan with identical coverage.
The Three Billing Problems That Hit Weight Loss and Metabolic Health Practices Hardest
1. GLP-1 Prior Authorization — The Most Rejected Drug Class in Outpatient Medicine
GLP-1 receptor agonists have among the highest prior authorization denial rates of any drug class. Most commercial payers require step therapy — documentation that the patient has tried and failed one or more alternative treatments — before approving a GLP-1. The step therapy requirements vary by payer, by plan, and by the specific drug requested.
Beyond step therapy, payers frequently require BMI documentation, comorbidity evidence (Type 2 diabetes, hypertension, cardiovascular disease), and specific ICD-10 diagnosis codes. A prior auth submitted with BMI and obesity code E66.01 but without documentation of a failed dietary intervention may be denied. The same submission with complete step therapy documentation passes. The documentation was always there — it just wasn’t assembled correctly for the payer’s criteria.
2. Coverage Whiplash — The Same Drug, Different Coverage, Different Patient
Ozempic and Mounjaro were originally approved for Type 2 diabetes. Their approved-for-weight-loss versions (Wegovy and Zepbound) have different coverage rules — and many employers have explicitly excluded the weight loss indication even when the diabetes indication is covered. A practice billing the same drug for two patients on the same payer but for different diagnoses must route the claims differently, apply different prior auth requirements, and bill different NDC codes.
Getting this wrong — billing Zepbound as if it were Mounjaro, or using the diabetes diagnosis code on a weight loss claim — generates either a denial or a compliance exposure.
3. Compounded Semaglutide — The Compliance Landmine
During the semaglutide shortage of 2023–2024, compounded semaglutide became widespread. Compounded medications are not FDA-approved and are not covered by most commercial insurers or Medicare. Practices that administered compounded semaglutide and billed it to insurance generated automatic denials — and potentially triggered fraud and abuse scrutiny depending on how the claims were coded. Now that the shortage has ended and FDA has restricted compound prescribing, practices that continued billing compounded formulations face additional compliance risk.
A weight management practice came to us after their prior authorization approval rate on GLP-1 prescriptions had dropped below 40%. Their biller was submitting auth requests with the diagnosis code and the drug name — nothing else. No step therapy documentation. No BMI history. No comorbidity evidence. No payer-specific criteria matching.
We restructured the prior auth workflow entirely. Before any GLP-1 auth was submitted, we pulled the specific criteria for that drug, that payer, and that plan — BMI threshold, required diagnoses, step therapy history required, documentation format. We built the auth package to match those criteria before submission.
Within 60 days the approval rate moved from 38% to 81%. The practice recovered $34,000 in previously denied drug claims through retroactive appeals. Monthly prescription revenue increased significantly because previously-denied patients could now access the medications their plan actually covered.
GLP-1 and Weight Loss Billing Denial Codes
| Denial Code | Reason | Fix |
|---|---|---|
| CO-50 | Non-covered service or no prior auth | Build auth to payer-specific criteria — step therapy, BMI, comorbidities |
| CO-151 | Medical necessity not established | Documentation must show BMI threshold met and qualifying diagnosis supported |
| CO-4 | Incorrect code or modifier | Diabetes vs weight loss diagnosis must match the specific drug indication being billed |
| CO-11 | Diagnosis inconsistent with procedure | E66.01 (morbid obesity), E11.x (Type 2 DM), Z68.x (BMI) — all must align with drug billed |
| CO-97 | Bundled with another service | Weight loss counseling codes (G0447) must be billed separately with appropriate diagnosis |
ICD-10 Codes Critical for GLP-1 and Weight Loss Billing
| Code | Description | When Used |
|---|---|---|
| E66.01 | Morbid (severe) obesity due to excess calories | BMI ≥ 40 or ≥ 35 with comorbidity — primary code for Wegovy/Zepbound auth |
| E66.9 | Obesity, unspecified | Weaker than E66.01 — many payers require E66.01 for GLP-1 approval |
| E11.x | Type 2 diabetes mellitus | Required for Ozempic/Mounjaro auth — diabetes indication |
| Z68.xx | Body mass index | Always include with obesity codes — payers use this to verify BMI threshold |
| E78.5 | Hyperlipidemia, unspecified | Comorbidity supporting medical necessity for GLP-1 |
| I10 | Essential hypertension | Comorbidity supporting medical necessity for GLP-1 |
Frequently Asked Questions
Is GLP-1 billing covered by insurance?
Coverage varies dramatically by payer and plan. Most commercial payers cover GLP-1s for Type 2 diabetes with prior authorization. Coverage for weight loss (Wegovy, Zepbound) is more restrictive — many plans explicitly exclude it, particularly employer self-funded plans. Medicare covers Ozempic and Mounjaro for diabetes but as of 2026 does not cover weight loss medications. Medicaid coverage varies by state.
How long does GLP-1 prior authorization take?
Most commercial payers have a 1–7 day turnaround on initial GLP-1 auth requests. Incomplete submissions — missing step therapy documentation or BMI evidence — extend this to 14–30 days or result in outright denial. A properly assembled auth package with payer-specific documentation routinely approves in 2–5 days.
What EHR systems do your weight loss billing specialists support?
Epic, athenahealth, eClinicalWorks, NextGen, Practice Fusion, and AdvancedMD. Weight loss practices also frequently use DrChrono and Hint Health — our billers are trained on both.
GLP-1 billing is a documentation and prior auth problem, not a coding problem. The right documentation, assembled for the right payer criteria, approves. Book a free 15-minute call — or start the 4-week free pilot.
Related Specialty Billing Services
GLP-1 and weight loss billing shares prior authorization complexity with other metabolic specialty areas. See our guides for Family Practice Billing Services — where GLP-1 prescribing is most common — and Internal Medicine Billing Services for practices managing diabetes and metabolic comorbidities alongside weight management.